Nucleic Acid-Based Vaccines as an Approach to Immunization Against Human Immunodeficiency Virus Type-1

  • M. L. Bagarazzi
  • J. D. Boyer
  • V. Ayyavoo
  • D. B. Weiner
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 226)


The spread of HIV-1 has resulted in significant morbidity and mortality worldwide. Traditional therapeutic approaches have included chemotherapy directed at several different viral components either alone or in combination. Studies evaluating combinations of two or three different anti-retroviral agents have recently generated optimism regarding the ability to control viral replication in vivo. It is too early to tell whether this approach is capable of controlling established infection without additional measures including immunotherapy. In any event, the majority of the worldwide at-risk population will not have easy access to these expensive therapeutic regimens. If achievable, protective vaccination represents the best solution to the worldwide problem of infection with HIV-1 and any strategy designed to control the epidemic is likely to rely heavily on mass immunization campaigns (Musgrove 1993). Unfortunately, the effort to design effective vaccines for HIV-1 has encountered a number of significant obstacles. In a 1993 poll by the journal Science (Cohen 1993) 150 top AIDS researchers agreed that the most significant obstacle has been the lack of consistent correlates of protection from natural or experimental infection. It is therefore not surprising that a wide variety of therapeutic modalities have been proposed in pursuit of effective therapy for HIV-1 (Table 1).


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Simian Immunodeficiency Virus Genetic Vaccine Envelope Construct 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agadjanyan M, Trivedi NN, Levine W, Kim JJ, Kudchodkar S, Boyer JD, Bennett M, Ugen KE, Weiner DB (1997) HIV-2 expression vectors generate cross-strain humoral and cellular anti-HIV-2 and anti- SIV immune responses. In: Brown F, Chanock RM, Ginsberg HS, Norrby E (eds) Vaccines 97: molecular approaches to the control of infectious diseases. Cold Spring Harbor, pp 131–136Google Scholar
  2. Agy M, Frumkin LR, Corey L, et al. (1992) Infection of Macaca nemestrina by human immunodeficiency virus type 1. Science 257:103–106PubMedCrossRefGoogle Scholar
  3. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ (1995) Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342–1344PubMedCrossRefGoogle Scholar
  4. Anderson D, Politch JA, Martinez A, Van Voorhis BJ, Padian NS, O’Brien TR (1992) White blood cells and HIV-1 in semen from vasectomized seropositive men. Lancet 338:573–574CrossRefGoogle Scholar
  5. Autran B, Legac E, Blanc C, Debre P (1995) A ThO/Th2-like function of CD4 + /CD7- T helper cells from normal donors and HIV infected patients. J Immunol 154:1408–1417PubMedGoogle Scholar
  6. Ayyavoo V, Nagashunmugam T, Boyer JD, Sundarasamy M, Fernandes LS, Lee P, Lin J, Nguyen C, Chattergoon MA, Goedert JJ, Friedman H, Weiner DB (1997) Development of genetic vaccines for pathogenic genes: construction of attenuated Vif DNA immunization cassettes. AIDS (in press)Google Scholar
  7. Baba T, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM (1995) Pathogenicity of live attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820–1825PubMedCrossRefGoogle Scholar
  8. Baier M, Werner A, Bannert N, Metzner K, Kurth R (1995) HIV suppression by interleukin-16. Nature 378:563PubMedCrossRefGoogle Scholar
  9. Bakshi SS, Tetalli S, Abrams EJ, Paul MO, Pahwa SG (1995) Repeatedly positive human immunodeficiency virus type 1 DNA polymerase chain reaction in human immunodeficiency virus-exposed infants. Pediatr Infect Dis J 14:658–662PubMedCrossRefGoogle Scholar
  10. Barrett N, Eder G, Dorner F (1991) Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Biotech Therapeut 2:91–106Google Scholar
  11. Berman P, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW (1990) Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622–625PubMedCrossRefGoogle Scholar
  12. Bleul C, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829–832PubMedCrossRefGoogle Scholar
  13. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD+ 8 cytotoxic T- lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type-1 infection. J Virol 68:6103–6110PubMedGoogle Scholar
  14. Boyer J, Wang B, Ugen KE, Srikantan V, Gilbert L, Kudchokar S, Javadian MA, Dang K, Merva M, Newman M, Carrano R, Coney L, Weiner DB (1995) Induction of humoral and cellular immune responses to HIV-1 in cynomologus macaques and chimpanzees by in vivo DNA inoculation. In: Brown F, Chanock RM, Ginsberg HS, Norrby E (eds) Vaccines 95: molecular approaches to the control of infectious diseases. Cold Spring Harbor, New York, pp 99–101Google Scholar
  15. Boyer J, Wang B, Ugen K, Agadjanyan MG, Javadian MA, Frost P, Dang K, Carrano R, Ciccarelli R, Coney L, Williams WV, Weiner DB (1996) In vivo protective anti-HIV immune responses in nonhuman primates through DNA immunization. J Med Primatol 25:242–250PubMedCrossRefGoogle Scholar
  16. Boyer J, Ugen KE, Wang B, Agadjanyan MG, Bagarazzi ML, Chattergoon M, Frost P, Javadian MA, Williams WV, Ciccarelli RB, McCallus D, Coney L, and Weiner DB (submitted) DNA vaccination as an anti HIV immunotherapy in HIV-1 infected chimpanzees J Infect Dis (in press)Google Scholar
  17. Bruck C, Thiriart C, Delers A, et al. (1993a) Comparison of vaccine protection in chimpanzees immunized with two different forms of recombinant HIV-1 envelope glycoprotein. AIDS Res Hum Retroviruses 9:S110Google Scholar
  18. Bruck C, Thiriart C, Fabry L, (1993b) HIV-1 envelope elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. J Cell Biochem 17:88Google Scholar
  19. Bryson YJ, Pang S, Wei LS, Dickover R, Diagne A, Chen IS (1995) Clearance of HIV-1 in a perinatally infected infant. NEJM 332:833–838PubMedCrossRefGoogle Scholar
  20. Cao Y, Qin L, Zhang L, Safrit J, Ho DD (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type-1 infection. NEJM 332:201–208PubMedCrossRefGoogle Scholar
  21. Cheingsong-Papov R, Callow D, Beddows S, et al. (1992) Geographic diversity of human immunodeficiency virus type 1: serologic reactivity env epitopes and relationship to neutralization. J Infect Dis 165:256–261CrossRefGoogle Scholar
  22. Cheng-Mayer C, Homsy J, Evans LA, Levy JA (1988) Identification of human immunodeficiency virus subtypes and distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci - USA 85:2815–2819PubMedCrossRefGoogle Scholar
  23. Clerici M, Shearer GM (1993) A Th1→Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 14:107–111PubMedCrossRefGoogle Scholar
  24. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P (1995) Identification of RAN- TES, MIP-1a, MIP-1b as the major HIV-suppressive factors produced by CD+ 8 T cells. Science 270:1811–1815PubMedCrossRefGoogle Scholar
  25. Cohen J (1993) AIDS research: The mood is uncertain. Science 260:1254–1255PubMedCrossRefGoogle Scholar
  26. Coney L, Wang B, Ugen KE, Boyer JD, McCallus D, Srikantan V, Agadjanyan MG, Pachuk CJ, Herold K, Merva M, Gilbert L, Dang K, Moelling K, Newman M, Williams WV, Weiner DB (1994) Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo. Vaccine 12:1545–1550PubMedCrossRefGoogle Scholar
  27. Connor R, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935–944PubMedCrossRefGoogle Scholar
  28. Cranage M, Baskerville A, Ashworth AE, et al. (1992) Intrarectal challenge of macaques vaccinated with formalin inactivated simian immunodeficiency virus. Lancet 339:273–274PubMedCrossRefGoogle Scholar
  29. Cullen B, Greene WC (1990) Functions of the auxiliary gene products of the human immunodeficiency virus type 1. Virology 178:1–5PubMedCrossRefGoogle Scholar
  30. Daniel M, Kirchoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1941PubMedCrossRefGoogle Scholar
  31. Danko I, Fritz JD, Shoushu J, Hogan K, Latendresse JS, Wolff JA (1994) Pharmacologic enhancement of in vivo foreign gene expression in muscle. Gene Therapy 1:1–8Google Scholar
  32. Davis H, Michel ML, Whalen RG (1993) DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Mol Genetics 2:1847–1851CrossRefGoogle Scholar
  33. el-Amad Z, Murthy KK, Higgins K, Cobb EK, Haigwood NL, Levy JA (1995) Resistance of chimpanzees immunized with recombinant gpl20-SF2 to challenge by HIV-1SF2. AIDS 9:1313–1322PubMedCrossRefGoogle Scholar
  34. Emini E, Schleif WA, Nunberg JH, et al. (1992) Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728–730PubMedCrossRefGoogle Scholar
  35. Fan L, Peden K (1992) Cell-free transmission of Vif nmutants of HIV-1. Virology 190:19–29PubMedCrossRefGoogle Scholar
  36. Fauci A (1993) Multifactorial nature of HIV disease. Implications for treatment. Science 262:1011–1015PubMedCrossRefGoogle Scholar
  37. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872–877PubMedCrossRefGoogle Scholar
  38. Fisher A, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Rtaner L, Gallo RC, Wong-Staal F (1987) The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237:888–895PubMedCrossRefGoogle Scholar
  39. Fultz P, Srinivasan A, Greene CR, Butler D, Swenson RB, McClure HM (1987) Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. Journal of Virology 61:4026–4029PubMedGoogle Scholar
  40. Gabuzda D, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine W, Sodroski J (1992) Role of vif in replication of human immunodeficiency virus type-1 transmission in CD4+ lymphocytes. J Virology 66:6489–6495PubMedGoogle Scholar
  41. George J, Ou CY, Parekh B, et al. (1992) Prevalence of HIV-1 and HIV-2 mixed infections in Cote d’Ivoire. Lancet 340:337–339PubMedCrossRefGoogle Scholar
  42. Girard M, Kieny MP, Pinter A et al. (1991) Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 88:542–546PubMedCrossRefGoogle Scholar
  43. Girard M, Meignier B, Barre-Sinoussi F, Kieny M-P, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, Fultz PN (1995) Vaccine-induced protection of chimpanzees against infection by a heterologous Human immunodeficiency virus type-1. Journal of Virology 69:6239–6248PubMedGoogle Scholar
  44. Golding H, Robey FA, Gates III FT, Linder W, Beining PR, Hoffman T, Golding B (1988) Identification of homologous regions in human immunodeficiency virus 1 gp41 and human MHC class II ß 1 domain. J Exp Med 167:914–923PubMedCrossRefGoogle Scholar
  45. Graham B, Wright PF (1995) Candidate AIDS vaccines. NEJM 333:1331–1339PubMedCrossRefGoogle Scholar
  46. Graham B, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE and NIAID AVEG (1996) Safety and Immunogenicity of a candidate HIV-1 Vaccine in Healthy adults: Recombinant (RGP) 120. A randomized, double-blind trial. Ann Intern Med 125:270–279PubMedGoogle Scholar
  47. Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sekaly RP, Fauci AS (1994) Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 265:248–252PubMedCrossRefGoogle Scholar
  48. Greene W (1991) The molecular biology of human immunodeficiency virus type 1 infections. NEJM 324:308–317PubMedCrossRefGoogle Scholar
  49. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC (1992) Activation-induced death by apoptosis in CD+ 4 T cells from human immunodeficiency virus-infected asymptomatic individuals. Journal of Experimental Medicine 175:331–340PubMedCrossRefGoogle Scholar
  50. Haynes J, Fuller DH, Eisenbraun MD, Ford MJ, Pertmer TM (1994) Accell particle-mediated DNA immunization elicits humoral, cytotoxic and protective responses. AIDS Res Hum Retroviruses 10:S43–45PubMedGoogle Scholar
  51. Hilleman MR (1992) Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS. Vaccine 10:1053–1058PubMedCrossRefGoogle Scholar
  52. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CDj lymphocytes in HIV-1 infection. Nature 373:123–126PubMedCrossRefGoogle Scholar
  53. Hulskotte EG, Geretti A-M, Siebelink KH, van Amerongen G, Cranage MP, Rud EW, Norley SG, de Vries P, Osterhaus AD (1995) Vaccine-induced virus neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with Simian immunodeficiency virus SIVmac32H(J5). Journal of Virology 69:6289–6296PubMedGoogle Scholar
  54. Johnson P, Montefiori DC, Goldstein S, Hamm TE, Zhou J, Kitov S, Haigwood NL, Misher L, London WT, Gerin JL et al. (1992) Inactivated whole virus vaccine derived from a proviral clone of simi- animmunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci USA 89:2175–2179PubMedCrossRefGoogle Scholar
  55. Jowett J, Planelles V, Poon B, Shah NP, Chen ML, Chen ISY (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69:6304–6313PubMedGoogle Scholar
  56. Katzenstein D, Vujcic LK, Latif A, Boulos R, Halsey NA, Quinn TC, et al. (1990) Human immunodeficiency neutralizing antibodies in sera from North Americans and Africans emergence of neutralization. J Acquir Immune Syndr 3:810–816Google Scholar
  57. Kestler H, Ringler DJ, Mori K, Panicalli DL, Sehgai PK, Daniel MD, Desrosiers RC (1991) Importance of the nef gene for maintenance of high virus loads and for the development of AIDS. Cell 65:651–662PubMedCrossRefGoogle Scholar
  58. Kim J, Chattergoon M, Ayyavoo V, Bagarazzi ML, Boyer JD, Wang B, Weiner DB (1997a) Development of a multi-component candidate vaccine for HIV-1. Vaccine 15:879–883PubMedCrossRefGoogle Scholar
  59. Kim J, Bagarazzi ML, Hu Y, Trivedi N, Chattergoon MA, Dang K, Agadjanyan MG, Mahalingam S, Boyer JD, Wang B, Weiner DB (1997b) Engineering of in vivo immune responses to DNA immunization via co-delivery of costimulatory molecule genes. Nature Biotech (in press)Google Scholar
  60. Kim J, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB (1997c) In vivo engineering of a cellular immune response by co-administration of IL-12 expression vector with a DNA immunogen. J Immunol 158:816–826PubMedGoogle Scholar
  61. Kim S, Ikeuchi K, Byrn R, Groopman J, Baltimore D (1989) Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86:9544–9548PubMedCrossRefGoogle Scholar
  62. Kirchoíf F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC (1995) Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. NEJM 332:228–232CrossRefGoogle Scholar
  63. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM (1990) The human immunodeficiency virus type-1 specific protein Vpu is required for efficient virus mutation and release. J Virol 64:621–629PubMedGoogle Scholar
  64. Koup R, Safrit JT, Cao Y, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary Human immunodeficiency virus type-1 syndrome. J Virol 68:4650–4655PubMedGoogle Scholar
  65. Learmont J, Tindall B, Evans L, Cunningham A, Cunningham P, Wells J, Penny R, Kaldor J, Cooper DA (1992) Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340:863–867PubMedCrossRefGoogle Scholar
  66. Levine B, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, Wagner KF, Mayers DL, Burke DS, Weislow OS, St. Louis DC, June CH (1996) Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272:1939–1943PubMedCrossRefGoogle Scholar
  67. Levy D, Refaeli Y, Weiner DB (1995) The vpr regulatory gene of human immunodeficiency virus. In: Chen I, Koprowski H, Srinivasan A, Vogt PK (eds) Transacting Functions of Human Retroviruses. Springer, Berlin, Heidelberg, New York 193:209–236Google Scholar
  68. Levy DN, Fernandes LS, Williams WV and Weiner DB (1993) Induction of cell differentiation by human immunodeficiency virus 1vpr. Cell 72:541–550PubMedCrossRefGoogle Scholar
  69. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J (1992) Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 5:639–646PubMedGoogle Scholar
  70. Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL (1995) Use of DNAs expressing HIV-1 env and non-infectious HIV-1 particles to raise antibody responses in mice. Virology 209:147–154PubMedCrossRefGoogle Scholar
  71. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, Robinson HL (1996) Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 70:3978–3991PubMedGoogle Scholar
  72. MacGregor R, Gluckman S, Lacy K, Wang B, Ugen K, Chattergoon M, Bagarazzi ML, Williams W, Ginsberg R, Higgins T, Boyer JD, Weiner DB (1996a) A DNA plasmid vaccine for HIV-1: experience in the first human trial indicates humoral and cell-immune responses. Fourth Conference on Retroviruses and Opportunistic Infections, Washington DCGoogle Scholar
  73. MacGregor R, Gluckman S, Lacy K, Kaniefski B, Boyer JD, Wang B, Bagarazzi ML, Williams WV, Francher D, Ginsberg R, Higgins T, Weiner DBU (1996b) First human trial of a facilitated DNA plasmid vaccine for HIV-1: safety and host response. XI International Conference on AIDS, VancouverGoogle Scholar
  74. Mackewicz CE, Ortega H, Levy JA (1994) Effect of cytokines on HIV replication in CD+ 4 lymphocytes: lack of identity with the CD+ 8 cell antiviral factor. Cell Immunol 153:329–343PubMedCrossRefGoogle Scholar
  75. Malim M, Hauber J, Le SY, Maizel JV, Cullen BR (1989) The HIV-1 rev trans-activator acts through a structured target sequence to activate a nuclear export of unspliced viral mRNA. Nature 338:254–257PubMedCrossRefGoogle Scholar
  76. Michael N, Chang G, D’Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, Schwartz DH (1995) Defective accessory genes in a human immunodeficiency vitus type-1 infected long-term survivor lacking recoverable virus. J Virol 69:4228–4236PubMedGoogle Scholar
  77. Musgrove P (1993) Investing in health the 1993 world development report of the World Bank. Bulletin of the Pan-American Health Organization 27:284–286PubMedGoogle Scholar
  78. Narayan O, Joag SV, Stephens EB (1995) Selected models of HIV-induced neurological disease. Current topics in microbiology and immunology, Springer, Berlin, Heidelberg, New York 202:151–166Google Scholar
  79. Nixon D, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ (1988) HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336:484–487PubMedCrossRefGoogle Scholar
  80. Novembre F, O’Neil SP, Saucier M, Anderson DC, Klumpp SA, Brown CR, Hart CA, Guenther PC, Swenson RB, McClure HM (1996) Pathogenic HIV-1 infection in chimpanzees. Fourteenth annual symposium on nonhuman primate models for AIDS. Portland, ORGoogle Scholar
  81. Oberlin E, Amara A, Bacherlerie F, Bessia C, Virelizier J-L, Arenzana-Seisdedos F, Schwartz O, Heard J-M, Clark-Lewis I, Legier DF, Loetscher M, Baggiolini M, Moser B (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833–835PubMedCrossRefGoogle Scholar
  82. Okuda K, Bukawa H, Hamajima K, Kawamoto S, Sekigawa K-I, Yamada Y, Tanaka S-I, Ishii N, Aoki I, Nakamura M, Yamamoto H, Cullen BR, Fukushima J (1995) Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses 11:933–943PubMedCrossRefGoogle Scholar
  83. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OY, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al. (1995) Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. NEJM 332:209–216PubMedCrossRefGoogle Scholar
  84. Pauza C, Emau P, Salvato MS, et al. (1993) Pathogenesis of SIVmac251 after atraumatic inoculation of the rectal mucosa in Rhesus monkeys. Journal of Medical Primatology 22:154–161PubMedGoogle Scholar
  85. Peeters M, Gershy-Dame GM, Fransen K, et al. (1992) Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d’Ivoire. Lancet 340:339–340PubMedCrossRefGoogle Scholar
  86. Phillips R, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453–459PubMedCrossRefGoogle Scholar
  87. Pialoux G, Excler JL, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP, et al. (1995) A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant gp160 (MN/LAI). AIDS Res and Human Retrovir 11:373–381CrossRefGoogle Scholar
  88. Pinto L, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, Shearer GM (1995) Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 96:867–876PubMedCrossRefGoogle Scholar
  89. Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, Norrby E (1991) Prevention of HIV-2 and SIVSM infection by passive immunization in cynomolgus monkeys. Nature 352:436–438PubMedCrossRefGoogle Scholar
  90. Refaeli Y, Levy DN, Weiner DB (1995) The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci USA 92:3621–3625PubMedCrossRefGoogle Scholar
  91. Riviere Y, Tannequ-Salvadori F, Regnault A, Lopez A, Sansonetti P, Guy B, et al. (1989) Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing Gag and Env proteins. Journal of Virology 63:2270–2277PubMedGoogle Scholar
  92. Rogel M, Wu LI, Emerman M (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69:882–888PubMedGoogle Scholar
  93. Rosen C (1991) Regulation of HIV gene expression by RNA-protein interaction. Trends Gen 7:9–14CrossRefGoogle Scholar
  94. Rosenthal K (1993) Recombinant adenoviruses: A vector for all seasons. AIDS Res Hum Retroviruses 9:S28Google Scholar
  95. Rowland-Jones S, Nixon DF, Aldhous MC (1993) HIV-specific cytotoxic T-cell activity in an HIV- exposed but uninfected infant. Lancet 341:860–861PubMedCrossRefGoogle Scholar
  96. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Allimore A, Corrah T, Takiguchi M, McMichael A, Whittle H (1995) HIV-specific T-cells in HIV-exposed but uninfected Gambian women. Nature Medicine 1:59–64PubMedCrossRefGoogle Scholar
  97. Saag M, Hahn BH, Gibbons JH, Li Y, Parks ES, Parks WP, Shaw GM (1988) Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 334:440–444PubMedCrossRefGoogle Scholar
  98. Schultz A, Hu S (1993) Primate models for HIV vaccines. AIDS 7:5161–5170CrossRefGoogle Scholar
  99. Schwartz D, Gorse G, Clements ML, Belshe R, Izu A, Duliege A-M, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, Matthews T (1993) Induction of HIV-1 neutralising and syncytium- inhibiting antibodies in uninfected recipients of HIV-1(IIIB) rpgl20 subunit vaccine. Lancet 342:69–73PubMedCrossRefGoogle Scholar
  100. Sheppard H, Bridges SH, Mathieson BJ, Walker MC, Weinhold K (1994) Conference on advances in AIDS vaccine development - 1993 Summary: correlates of HIV Immunity Working Group. AIDS Res Hum Retroviruses 10:S171–176PubMedGoogle Scholar
  101. Shibata R, Hoggan MD, Broscius C, Englund G, Theodore T, Buckler-White A, Arthur L, Israel Z, Schult A, Lane HC, Martin MA (1995) Isolation and characterization of a syncytium-inducing, macrophage/T-cell line tropic HIV-1 isolate that readily infects chimpanzee cells in vitro and in vivo. Journal of Virology 69:4453–4462PubMedGoogle Scholar
  102. Tang D, Devit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152–154PubMedCrossRefGoogle Scholar
  103. Taylor R (1992) Does HIV-1 kill lymphocytes by inducing cell suicide? J NIH Res 4:65–69Google Scholar
  104. Thomason D, Booth FW (1990) Stable incorporation of a bacterial gene into adult rat skeletal muscle in vivo. Am J Cell Physiol 258:C578–581Google Scholar
  105. Ugen K, Goedert JJ, Boyer JD, Refaeli Y, Frank I, Williams WV, Willoughby A, Landesman S, Mendez H, Rubinstein A, Keiber-Emmons T, Weiner DB (1992) Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 89:1923–1930PubMedCrossRefGoogle Scholar
  106. Ugen K, Boyer JD, Wang B, Gluckman S, Williams WV, Nyland S, Carmack B, Agadjanyan MG, Bagarazzi ML, Higgins T, Coney L, Ciccarelli R, Ginsberg R, MacGregor RR, Weiner DB (1997a) Facilitated nucleic acid vaccination of humans with an HIV-1 expressing DNA boosts immune responses against the envelope glycoprotein. In: Brown F, Chanock RM, Ginsberg HS, Norrby E (eds) Vaccines 97: molecular approaches to the control of infectious diseases. Cold Spring Harbor, pp 145–150Google Scholar
  107. Ugen K, Boyer JD, Wang B, Bagarazzi ML, Javadian MA, Frost P, Merva MM, Nyland S, Williams WV, Coney L, Ciccarelli R, Weiner DB (1997b) Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial. Vaccine 15:927–930PubMedCrossRefGoogle Scholar
  108. Ulmer J, Donnelly J, Parker SE, Rhodes GH, Feigner PL, Dwarki VL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749PubMedCrossRefGoogle Scholar
  109. von Schwedler U, Song J, Aiken C, Trono D (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 67:4945–4955Google Scholar
  110. Walker B, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT, Moss B (1988) HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64–66PubMedCrossRefGoogle Scholar
  111. Walker BD (1994) The rationale for immunotherapy in HIV-1 infection. J Acquir Immune Defic Syndr 7:S6–13PubMedGoogle Scholar
  112. Wang B, Boyer JD, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanyan MG, Ugen KE, Williams WV, Weiner DB (1993a) DNA inoculation induces neutralizing immune responses against Human immunodeficiency virus type 1 in mice and non-human primates. DNA Cell Biol 12:799–805PubMedCrossRefGoogle Scholar
  113. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB (1993b) Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:4156–4160PubMedCrossRefGoogle Scholar
  114. Wang B, Boyer JD, Ugen KE, Merva M, Dang K, Agadjanyan MG, Williams WV, Weiner DB (1994a) Analysis of antigen-specific immune responses induced through in vivo genetic inoculation. In: Brown F, Chanock RM, Ginsberg HS, Norrby E (eds) Vaccines 94: molecular approaches to the control of infectious diseases. Cold Spring Harbor, New York, pp 83–90Google Scholar
  115. Wang B, Merva M, Dang K, Ugen KE, Boyer JD, Williams WV, Weiner DB (1994b) DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells. AIDS Res Hum Retroviruses 10:S35–41PubMedCrossRefGoogle Scholar
  116. Wang B, Merva M, Dang K, Ugen KE, Williams WV, Weiner DB (1995a) Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Human Gene Ther 6:407–418CrossRefGoogle Scholar
  117. Wang B, Boyer JD, Srikantan V, Ugen KE, Gilbert L, Phan C, Dang K, Merva M, Agadjanyan MG, Newman M, Carrano R, McCallus D, Coney L, Williams WV, Weiner DB (1995b) Induction of humoral and cellular immune responses to the human immunodeficiency type-1 virus in non-human primates by in vivo DNA inoculation. Virology 211:102–112PubMedCrossRefGoogle Scholar
  118. Wang B, Boyer JD, Ugen KE, Srikantan V, Ayyavoo V, Agadjanyan MG, Williams WV, Newman M, Coney L, Carrano R, Weiner DB (1995c) Nucleic acid-based immunization against HIV-1: induction of protective in vivo immune responses. AIDS 9:S159–170PubMedGoogle Scholar
  119. Wang B, Ge YC, Palasanthiran P, Xiang S-H, Ziegler J, Dwyer DE, Randle C, Dowton D, Cunningham A, Saksena NK (1996) Gene defects clustered at the C-Terminus of the vpr gene of HIV-1 in longterm nonprogressing mother and child pair: In vivo evolution of vpr quasispecies in blood and plasma. Virology 223:224–232PubMedCrossRefGoogle Scholar
  120. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM (1995) Viral dynamics in human immunodeficiency virus type-1 infection. Nature 373:117–122PubMedCrossRefGoogle Scholar
  121. Yasutomi Y, Robinson HL, Lu S, Mustafa F, Lekutis C, Arthros J, Mullins JI, Voss G, Manson K, Wyand M, Letvin NL (1996) Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 70:678–681PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • M. L. Bagarazzi
    • 1
    • 2
  • J. D. Boyer
    • 1
    • 2
  • V. Ayyavoo
    • 1
    • 2
  • D. B. Weiner
    • 1
    • 2
  1. 1.Department of PediatricsAllegheny University of the Health SciencesPhiladelphiaUSA
  2. 2.Department of Pathology and Laboratory MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations